Liaoning Chengda Biotechnology Co Ltd
SSE:688739
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.14
34.17
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Liaoning Chengda Biotechnology Co Ltd
Liaoning Chengda Biotechnology Co Ltd
Operating Expenses
Liaoning Chengda Biotechnology Co Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
|
Operating Expenses
-¥884.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Operating Expenses
-¥23.5B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Operating Expenses
-¥2.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-71%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Operating Expenses
-¥3.1B
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Operating Expenses
-¥954.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-19%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Operating Expenses
-¥4.9B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-30%
|
|
Liaoning Chengda Biotechnology Co Ltd
Glance View
Liaoning Chengda Biotechnology Co., Ltd. is engaged in the research, development, manufacture and sale of vaccines. The company is headquartered in Shenyang, Liaoning and currently employs 1,663 full-time employees. The company went IPO on 2021-10-28. The firm's main products include rabies vaccine for human use, freeze-dried rabies vaccine for human use, inactivated Japanese encephalitis vaccine for human use and freeze-dried encephalitis inactivated vaccine. The firm's products include two brands: Chengda Suda and Chengda Libao.
See Also
What is Liaoning Chengda Biotechnology Co Ltd's Operating Expenses?
Operating Expenses
-884.8m
CNY
Based on the financial report for Dec 31, 2023, Liaoning Chengda Biotechnology Co Ltd's Operating Expenses amounts to -884.8m CNY.
What is Liaoning Chengda Biotechnology Co Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-13%
Over the last year, the Operating Expenses growth was -8%. The average annual Operating Expenses growth rates for Liaoning Chengda Biotechnology Co Ltd have been -7% over the past three years , -13% over the past five years .
You don't have any saved screeners yet
